Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

January 5, 2018: By Market Scope

Kala PharmaceuticalsKala Pharmaceuticals announced Jan. 5 that KPI-121 0.25% saw mixed results in its two Phase III clinical trials in dry eye disease, meeting three or four primary endpoints.

Kala CEO Mark Iwicki said the company would need to study the data more to decide the path forward, and he was unable to provide a timetable.

The company said it plans to seek a meeting with US regulators for guidance. Future options include conducting another study or submitting the data as is to the FDA.

The Waltham, Massachusetts, firm said it believes its cash balance of $114 million puts it in a strong position as it continues to advance its candidates.

Kala’s formulations use its mucus-penetrating particle (MPP) technology to enhance penetration of the steroid loteprednol etabonate in eye tissue.

Kala’s lead candidates are KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease; and INVELTYS (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery.

The dry eye candidate achieved statistical significance in both Phase III trials (STRIDE 1 and STRIDE 2) in the primary sign endpoint of improvement in conjunctival hyperemia at Day 15.

It showed statistical significance in the primary symptom endpoint of improvement in ocular discomfort at Day 15 in the first Phase III trial. In the second trial, it showed improvement, but not at a statistically significant level.

The trials were multicenter, randomized, double-masked, placebo-controlled studies comparing KPI-121 with placebo, each dosed four times a day for 14 days.

In both studies, KPI-121 0.25% was well-tolerated, with elevations of intraocular pressure similar to placebo.

Kala also announced Jan. 5 that the FDA had accepted INVELTYS’ submission for review and assigned a target action date of Aug. 24.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023